NASDAQ:SNCE

Science 37 (SNCE) Stock Forecast, Price & News

$0.41

+0.14 (+51.11%)

(As of 08/9/2023 ET)

Compare

Today's Range: $0.26
▼
$0.48
50-Day Range: $0.21
▼
$0.41
52-Week Range: $0.19
▼
$2.53

Volume: 27.92 million shs
Average Volume: 782,886 shs
Market Capitalization: $48.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.50

Science 37 MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 745.6% Upside
$3.50 Price Target
Short Interest: Healthy
0.72% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

450th out of 970 stocks

Commercial Physical Research Industry

10th out of 15 stocks

3.4

Analyst's Opinion

Consensus Rating
Science 37 has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.50, Science 37 has a forecasted upside of 745.6% from its current price of $0.41.
Amount of Analyst Coverage
Science 37 has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.72% of the float of Science 37 has been sold short.
Short Interest Ratio / Days to Cover
Science 37 has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Science 37 has recently increased by 8.41%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Science 37 does not currently pay a dividend.
Dividend Growth
Science 37 does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNCE.

3.0

News and Social Media Coverage

News Sentiment
Science 37 has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Science 37 this week, compared to 1 article on an average week.
Search Interest
10 people have searched for SNCE on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
MarketBeat Follows
1 people have added Science 37 to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Science 37 insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Science 37 is held by insiders.
Percentage Held by Institutions
44.61% of the stock of Science 37 is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Science 37 is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Science 37 is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Science 37 has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Science 37 (NASDAQ:SNCE) Stock

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

SNCE Price History

30 days | 90 days | 365 days | Advanced Chart

SNCE Stock News Headlines

August 9, 2023 | investing.com

Science 37 Holdings (SNCE) Earnings Dates & Reports

August 8, 2023 | finanznachrichten.de

Science 37, Inc.: Science 37 Reports Second Quarter 2023 Financial Results

August 10, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

August 8, 2023 | msn.com

Science 37 GAAP EPS of -$0.17 misses by $0.02, revenue of $15.35M beats by $2.78M

August 8, 2023 | finance.yahoo.com

Science 37 Reports Second Quarter 2023 Financial Results

August 7, 2023 | benzinga.com

Science 37 Hldgs Earnings Preview

August 7, 2023 | americanbankingnews.com

Science 37 (SNCE) Scheduled to Post Quarterly Earnings on Tuesday

July 25, 2023 | finance.yahoo.com

Science 37 to Report Second Quarter 2023 Financial Results on August 8, 2023

August 10, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

July 11, 2023 | finance.yahoo.com

Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)

July 11, 2023 | finance.yahoo.com

Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)

July 8, 2023 | finanznachrichten.de

Science 37, Inc.: Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 18, 2023 | finance.yahoo.com

Science 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"

May 15, 2023 | finanznachrichten.de

Science 37, Inc.: Science 37 Reports First Quarter 2023 Financial Results

May 15, 2023 | finance.yahoo.com

Science 37 Reports First Quarter 2023 Financial Results

May 14, 2023 | marketwatch.com

8-K: Science 37 Holdings, Inc.

May 2, 2023 | finance.yahoo.com

Science 37 Joins Partnership in Support of White House CancerX and Cancer Moonshot

May 1, 2023 | finance.yahoo.com

Science 37 to Report First Quarter 2023 Financial Results on May 15, 2023

April 25, 2023 | finance.yahoo.com

Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity

April 20, 2023 | finance.yahoo.com

Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical Research

April 18, 2023 | finance.yahoo.com

Science 37 Adds New Head of Quality, Irena Lambridis

April 14, 2023 | markets.businessinsider.com

Science 37 (SNCE) Gets a Buy from Craig-Hallum

April 12, 2023 | bizjournals.com

RTP firm cutting jobs in US and Europe, will look elsewhere for cheaper labor

April 11, 2023 | finance.yahoo.com

Science 37 Unveils Three Global Centers of Excellence to Drive Efficiency, Speed and Quality

April 11, 2023 | finance.yahoo.com

Science 37 to Host Business Update Call on April 12, 2023

March 13, 2023 | investorplace.com

Why Is Science 37 (SNCE) Stock Up 9% Today?

March 8, 2023 | insidermonkey.com

Science 37 Holdings, Inc. (NASDAQ:SNCE) Q4 2022 Earnings Call Transcript

See More Headlines

Receive SNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter.

SNCE Company Calendar

Last Earnings: 5/15/2023
Today: 8/09/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNCE
CUSIP: N/A
CIK: 1819113
Web: www.lifesciacquisition.com
Phone: 984-377-3737
Fax: N/A
Employees: 460
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.50
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +745.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,990,000.00
Net Margins: -183.86%
Pretax Margin: -183.99%
Return on Equity: -72.19%
Return on Assets: -58.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.85
Quick Ratio: 5.85

Sales & Book Value

Annual Sales: $70.15 million
Price / Sales: 0.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.83 per share
Price / Book: 0.50

Miscellaneous

Outstanding Shares: 116,760,000
Free Float: 108,237,000
Market Cap: $48.33 million
Optionable: Not Optionable
Beta: 1.29

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. David Coman (Age 53)
CEO & Director
Comp: $796.13k

Ms. Christine A. Pellizzari J.D. (Age 55)
Chief Legal & HR Officer and Sec.
Comp: $521.58k

Ms. Darcy Forman (Age 47)
Chief Delivery Officer
Comp: $550.58k

Mr. Mike Zaranek (Age 52)
Chief Financial Officer

Troy Bryenton
Chief Technology Officer

Irena Lambridis
VP and Head of Quality Assurance & Compliance

Ms. Margie Gimbel Kooman
VP of Marketing & Communications

Mr. Drew Bustos
Chief Strategy & Marketing Officer

Mr. Jonathan Cotliar M.D. (Age 51)
Chief Medical Officer

Mr. Michael Shipton (Age 51)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SNCE Stock - Frequently Asked Questions

Should I buy or sell Science 37 stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNCE shares.
View SNCE analyst ratings or view top-rated stocks.
What is Science 37's stock price forecast for 2023?: 4 Wall Street analysts have issued twelve-month price objectives for Science 37's shares. Their SNCE share price forecasts range from $1.00 to $7.00. On average, they expect the company's stock price to reach $3.50 in the next year. This suggests a possible upside of 745.6% from the stock's current price.
View analysts price targets for SNCE or view top-rated stocks among Wall Street analysts.
How have SNCE shares performed in 2023?: Science 37's stock was trading at $0.4152 at the beginning of 2023. Since then, SNCE stock has decreased by 0.3% and is now trading at $0.4139.
View the best growth stocks for 2023 here.
When is Science 37's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SNCE earnings forecast.
How were Science 37's earnings last quarter?: Science 37 Holdings, Inc. (NASDAQ:SNCE) issued its earnings results on Monday, May, 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The company earned $14.09 million during the quarter, compared to analysts' expectations of $12.10 million. Science 37 had a negative trailing twelve-month return on equity of 72.19% and a negative net margin of 183.86%.
What guidance has Science 37 issued on next quarter's earnings?: Science 37 issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60.00 million-$60.00 million, compared to the consensus revenue estimate of $56.94 million.

What is Science 37's stock symbol?: Science 37 trades on the NASDAQ under the ticker symbol "SNCE."
How do I buy shares of Science 37?: Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Science 37's stock price today?: One share of SNCE stock can currently be purchased for approximately $0.41.
How much money does Science 37 make?: Science 37 (NASDAQ:SNCE) has a market capitalization of $48.33 million and generates $70.15 million in revenue each year. The company earns $-50,990,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis.
How many employees does Science 37 have?: The company employs 460 workers across the globe.
How can I contact Science 37?: Science 37's mailing address is 250 W 55TH ST. #3401, NEW YORK NY, 10019. The official website for the company is www.lifesciacquisition.com. The company can be reached via phone at 984-377-3737 or via email at investment@lifesciacquisition.com.

This page (NASDAQ:SNCE) was last updated on 8/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial